Ab Initio publishes article in Inhalation Magazine | Fast-tracking inhalation product development using in vitro tools

Written By PY

Ab Initio Pharma CSO, Hui Xin Ong (YY) and Senior Scientist Trisha Almazi discuss how cell based in vitro cell models can be used to evaluate toxicity, transport and uptake of orally and nasally inhalers therapeutics.

Key messages:

Respiratory and nasal cell models can be used

  • as a physiological relevant in vitro platforms for characterisation of inhalation formulations

  • as a FastTrack Platform for developing inhalation and nasal products

  • to reduces the use of animals in pre-clincical product development

Learn more about Ab Initio Pharma’s pre-clinical services and a link to the article here

About Inhalation Magazine: Inhalation is the only trade magazine devoted exclusively to readers involved in research and development and manufacturing of orally inhaled and nasal delivered pharmaceuticals (OINDPs) read Inhalation Magazine here

PY
Previous

Learn how Ab Initio partners with leaders to produce next generation GMP MDIs ready for the clinic
Next

Ab Initio partners on $1m grant to develop innovative COVID vaccine.